NPC
PVCT

National Planning Corporation’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

National Planning Corporation’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-4,128
Closed -$3.38K – 2526
2014
Q4 		$3.38K Buy
+4,128
New +$3.77K ﹤0.01% 2453

Other funds holding PVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

National Planning Corporation's PVCT Position: Q1 2015 in Review

National Planning Corporation sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q1 2015, closing a stake of 4,128 shares — an estimated $3.38K sold.

National Planning Corporation first reported a position in PVCT in Q4 2014 and held it in 1 quarter. The position peaked at $3.38K in Q4 2014. 35 funds tracked by Wall St. Rank hold PVCT as of Q1 2015.

  • National Planning Corporation reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q1 2015 after selling out during the quarter.
  • National Planning Corporation sold 4,128 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q1 2015, an estimated $3.38K.
  • National Planning Corporation first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q4 2014 and held it in 1 quarter.
  • National Planning Corporation's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $3.38K in Q4 2014.
  • 35 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q1 2015.

Based on National Planning Corporation's 13F filing for Q1 2015, filed 12 May 2015.